Levels of depression in transgender people and its predictors: Results of a large matched control study with transgender people accessing clinical services

This item was submitted to Loughborough University's Institutional Repository by the/an author.

Citation: WITCOMB, G.L. ...et al., 2018. Levels of depression in transgender people and its predictors: Results of a large matched control study with transgender people accessing clinical services. Journal of Affective Disorders, 235, pp.308-315.

Additional Information:

- This paper was accepted for publication in the journal Journal of Affective Disorders and the definitive published version is available at https://doi.org/10.1016/j.jad.2018.02.051

Metadata Record: https://dspace.lboro.ac.uk/2134/31994

Version: Accepted for publication

Publisher: © Elsevier

Rights: This work is made available according to the conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Full details of this licence are available at: https://creativecommons.org/licenses/by-nc-nd/4.0/

Please cite the published version.
Levels of depression in transgender people and its predictors: Results of a large matched control study with transgender people accessing clinical services.

Gemma L. Witcomb¹, Walter Pierre Bouman², Laurence Claes³,⁴, Nicola Brewin², John R. Crawford⁵, & Jon Arcelus²,⁶.

¹School of Sport, Exercise, and Health Sciences, Loughborough University, Loughborough, United Kingdom
²Nottingham Centre for Transgender Health, Nottingham, United Kingdom
³Faculty of Psychology and Educational Sciences, KU Leuven, Leuven, Belgium
⁴Faculty of Medicine and Health Sciences (CAPRI), University of Antwerp, Antwerp, Belgium
⁵School of Psychology, University of Aberdeen, Aberdeen, United Kingdom
⁶Institute of Mental Health, Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham, United Kingdom

Corresponding author: Dr Walter Pierre Bouman, Nottingham Centre for Transgender Health, 12 Broad Street, Nottingham NG1 3AL, United Kingdom; Tel. +44 115 8760160; Fax: +44 115 8760160; E-mail: walter.bouman@doctors.org.uk
Abstract

Background
Depression is a serious disorder which significantly impacts wellbeing and quality of life. Studies exploring mental wellbeing in the transgender population are mostly limited by small, non-homogenous samples and lack of matched controls. This study aimed to address these limitations and explore depression rates in a large sample of transgender people, compared with matched controls from the general population, as well as factors predicting depression in those taking cross-sex hormone treatment (CHT) compared to those not.

Methods
Transgender individuals (n=913) completed a measure of depression, measures which predict psychopathology (self-esteem, victimization, social support, interpersonal problems), and information regarding CHT use. Participants were matched by age and experienced gender with adults from the general population who had completed the measure of depression.

Results
Individuals were categorized as having no, possible or probable depressive disorder. Transgender individuals not on CHT had a nearly four-fold increased risk of probable depressive disorder, compared to controls. Older age, lower self-esteem, poorer interpersonal function and less social support predicted depressive disorder. Use of CHT was associated with less depression.

Limitations
Participants were attending a national gender identity service and therefore represent only a sub-group of transgender people. Due to the cross-sectional design,
longitudinal research is required to fully confirm the finding that CHT use reduces depression.

**Conclusion**

This study confirms that non-treated transgender individuals have an increased risk of a depressive disorder. Interventions offered alongside gender affirming treatment to develop interpersonal skills, increase self-esteem and improve social support may reduce depression and prepare individuals for a more successful transition.

**Key words:** Transgender; depression; self-esteem; social support; interpersonal function; cross-sex hormone treatment
1. Introduction

Depression is one of the most commonly diagnosed mental disorders (Kessler et al., 2012) and one of the most intensely researched. Recent estimates suggest that depression affects around 350 million people globally and is one of the leading cause of disability worldwide (WHO, 2016). Efficaciousness of treatments (NICE, 2009) as well as identification of co-morbid disorders (such as anxiety, obsessive-compulsive disorder, and substance abuse), has led to a better understanding of this mental disorder. Depression has been found to be associated with a number of co-occurring factors, such as age (Stordal et al., 2003), being female (Girgus et al., 2017; Kessler, 2003), experiencing victimization (Collier, 2013), having less social support (Paykel, 1994), lower self-esteem (Sowislo & Orth, 2013) and poorer interpersonal functioning (Barrett & Barber, 2007; McFarquhar et al., 2018). As a result, some populations may be more at risk than others.

Indeed, depression has been found to be more prevalent in the LGBTQ (Lesbian, Gay, Bisexual, Transgender and Questioning) population compared to the general population (Marshal et al., 2011). It has been hypothesized that vulnerability to develop depression in the LGBTQ population relates to the stress experienced by this group. The Minority Stress model (Meyer, 1995) suggests that this can largely be explained by stressors induced by a hostile, homophobic, trans phobic culture, which often results in a lifetime of harassment, abuse, victimization, and discrimination (Meyer et al., 2008). However, in many studies that have explored the mental health of LGBT individuals, the samples have predominately consisted of LGB individuals, and have included very small numbers of transgender people (Haas et al., 2010; Walls et al., 2010). Thus, the prevalence, seriousness, and comorbidity
of depression in the transgender population is still poorly researched and understood.

Transgender individuals are those whose gender identity does not match the sex assigned at birth (Bouman & Arcelus, 2017). Some may present themselves in a way that is not within the traditional binary dichotomy of man/woman (Warren et al., 2016; Richards et al., 2016). A number of transgender people will choose to use cross-sex hormone treatment (CHT) and/or gender affirming surgery to feminize or masculinize their bodies (Richards et al., 2016). Although recent systematic reviews have found that prevalence rates of transgender people is not high (Arcelus et al., 2015), most studies are limited by focusing on those attending services. Recent population studies indicate a clear increase in the number of transgender people in society (Arcelus et al., 2015; Flores et al., 2016; Kuyper & Wijsen, 2014) and evidence of this is the increase in prevalence rates of transgender individuals presenting to specialist transgender health services in western countries (Arcelus et al., 2015; Collin et al., 2016). Recent studies have found that 0.6% of the American population is described as transgender (Flores et al., 2016). Population studies in the Netherlands and Belgium show similar results (Kuyper & Wijsen, 2014; Van Caenegem, 2015). Transgender people describe personal struggles with coming out and disclosing their gender identity (Bockting & Coleman, 2016), with many experiencing discrimination and victimization (Adams et al., 2016; Bockting et al., 2014; Claes et al., 2015), including rejection from family and others (Koken et al., 2009).

It is, therefore, not surprising that transgender people are reported to suffer from a high prevalence of mental health problems, most notably anxiety and depression
Bockting et al., 2013; Bouman et al., 2016; Davey et al., 2014; Dhejne et al., 2016; Heylens et al., 2014; Hoffman, 2014; Millet et al., 2016), low self-esteem (Erich et al., 2010), self-harm (Davey et al., 2016; Marshall et al., 2016) and disordered eating and poor body image (van de Grift, 2016a, 2016b; Witcomb et al., 2015). Previous research with cross-sectional data has found that transgender individuals have high levels of anxiety; higher than found in other groups or normative data (Bouman et al., 2016a).

In relation to depression, while the number of studies are limited, those that have been carried out report associations between depression and frequent experiences of discrimination in employment and housing, sexual violence, physical and verbal abuse, societal harassment related to gender presentation, a perceived need to keep one’s transgender identity a secret, higher levels of minority stress and lower levels of social support [e.g., Bazargan & Galvin, 2012; Bockting et al., 2014; Bouman et al., 2016b; Clements-Nolle et al., 2006; Huffaker & Kwon, 2016; Leppel, 2016; McNeil et al., 2012; Nemoto et al., 2011]. Hoffman (2014) recently reviewed the literature on depression in transgender women and reported that interactions with other people – both positive via social support and negative via discrimination and abuse – are important predictors of depression.

Given that depression may be related to pre-transition problems or the transition itself, many studies have compared prevalence of depression between individuals who have and have not received gender affirming medical treatment (i.e., either cross-sex hormone treatment (CHT) or CHT and gender affirming surgery (GAS) (Bouman et al., 2016b; Colizzi et al., 2014; Davis & Colton Meier, 2014; De Vries et al., 2014; Gómez-
Gil et al., 2012; Heylens et al., 2014; Colton Meier et al., 2011) in order to try to ascertain whether depressive symptomology is alleviated by such interventions. Although the majority of these studies show that transgender people not on CHT experience higher levels of depressive symptomatology than those on treatment (Colizzi et al., 2014; Davis & Colton Meier, 2014; De Vries et al., 2014; Gómez-Gil et al., 2012; Heylens et al., 2014; Colton Meier et al., 2011), the results are not consistent [e.g., Reisner et al., 2015). Indeed, the association between CHT and depression is likely to be influenced by stigma (felt and enacted) (Bockting et al., 2013) which may not always be lessened by receiving cross-sex hormone treatment or gender affirming surgery, nor may be wanted by all transgender people (Beek et al., 2015).

While these studies begin to paint a picture of the prevalence of depressive symptomology in the transgender population, there are a number of methodological limitations in the findings of the aforementioned studies. Firstly, the studies often include a non-heterogeneous group of transgender people, for example, those at different stages of transition (e.g., Bockting et al., 2014). This is the case for the studies exploring the use of the CHT and may go some way to explain the inconsistencies found. Transition stage is a crucial variable as those people further through their journey may have developed increased resilience over time and increased social support and affirmation of their gender identity (Bockting & Coleman, 2016). This is therefore likely to be an important variable that needs to be considered and controlled for when exploring aspects of mental health and wellbeing in the transgender population. Secondly, while some have used comparison groups, which provide a degree of control, none of these studies have used matched control data to control for known factors that affect depression symptoms, such as age and gender (Arbus et al.,
2014; Baxter et al., 2013). Finally, studies most often tend to involve small sample sizes which may undermine reliability (Button et al., 2013).

To address the aforementioned limitations of small sample size, lack of matched control groups and non-homogeneity, the current study aimed to recruit a large cohort of adult transgender individuals, all at the same stage of accessing clinical services, and to compare them to a large cohort of adults recruited from the general population, matched by age and (experienced) gender. The study had three aims. Firstly, to determine the levels of depressive symptomatology suggesting no, possible and probable depressive disorder in non-treated transgender people accessing treatment (thereby excluding any transgender person who may already be on cross-sex hormones) and to compare them with a cisgender (person whose gender identity corresponds with their birth sex) matched sample from the general population. Secondly, to investigate the predictive role of variables known to be associated with depressive symptoms (age, assigned gender, self-esteem, social support, interpersonal function, and victimisation, and the use of CHT). Finally, to investigate differences in depressive scores between transgender people on cross-sex hormone treatment (CHT) with those not on cross-sex hormone treatment (non-CHT).

Based on the literature on depression in the transgender population it was hypothesized that levels of depression will be higher in the transgender population compared to the general population, and will be associated with older age, decreased self-esteem and social support, discrimination, lower levels of interpersonal function and lack of CHT treatment. No prediction was made regarding potential differences between transgender males and females. Physiological evidence points towards a
possible genetic aetiology for depression which might manifest in differences based on birth assigned gender (e.g., Bangasser et al., 2016), while more social explanations may predict differences based on levels of hardship and discrimination experienced (expected to be higher for both cis and transgender women).

2. Methods

2.1 Participants and Procedures

2.1.1. Transgender participants

The sample consisted of all individuals (n=1069) invited for assessment at a national transgender health service in the United Kingdom (UK) during a 3-year period from November 2012 to October 2015, who self-identified as transgender. Prior to the clinical assessment every patient was sent a questionnaire pack, consisting of the standard demographic and history questionnaires required as part of routine care, as well as the study questionnaires, an information sheet and consent form. If consent was given, participants returned all of the questionnaires by mail, in the envelope provided. If consent was not given, participants returned only the standard questionnaire. The refusal/non-response rate was 2.3%. The study received ethical approval from the NHS Ethics committee and from the Research and Development Department from the Nottinghamshire Healthcare NHS Foundation Trust in line with Health Research Authority guidance (Health Research Authority, 2013). For the first aim of the study, in order to have a homogenous group, only those individuals who were not on any cross-sex hormones (non-CHT) before assessment were eligible to be included in this analysis. For the second and third aims, the full sample was included.
2.1.2. Control group

A sample of 3816 male and female adults from the general UK population who were recruited between 2006 and 2009 for a different study (Crawford, 2009) were used as controls and matched by age and gender to the transgender sample. The normative data of the control sample was purposefully broad, having selected a wide representation of the general adult UK population, in terms of age, education, and gender (although, in most cases, females were over sampled). Participants were recruited from a variety of sources, including both large and small businesses, public service organizations, community centres, and recreational groups. Both urban/suburban and rural-semi-rural locations were represented in the sample, although recruitment was greater in the former locations. Participants were invited to complete the Hospital Anxiety and Depression Scale (Zigmond & Snaith, 1983) and, if they consented, to return completed questionnaires in a sealed envelope. The questionnaires were filled out anonymously. The combined refusal/non-return rates ranged from approximately 17% to 21%. Ethical approval for this study and the previous studies had been obtained from the Psychology Ethics Committee of the University of Aberdeen, Aberdeen, United Kingdom.

2.2. Main Outcome Measures

2.2.1. The Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983) is a 14-item self-report screening scale that was originally developed to indicate the possible presence of anxiety and depression states in the setting of a medical non-psychiatric outpatient clinic. The HADS consists of two subscales, HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D). For this study only the subscale of
depression will be used. This subscale has seven items, rated on a 4-point Likert scale (ranging from, as much as I always do (0); not quite so much (1); definitely not so much (2); to not at all (3)), indicating symptoms of depression during the preceding week. A score of 0-7 on either scale is regarded as being in the non-clinical range (no symptoms), a score of 8-10 is suggestive of the presence of a depressive disorder (possible symptoms), and a score of 11 or higher indicates the probable presence of a depressive disorder (symptoms). Maximum subscales scores are 21. The HADS was found to perform well in assessing the symptom severity and caseness of depressive disorders in both somatic, psychiatric and primary care patients and in the general population (Bjelland et al., 2002) and it has been previously used with transgender individuals (Colizzi et al., 2014; Gómez-Gil et al., 2012). A number of researchers have explored HADS data to establish the cut-off points for caseness of depression and a systematic review of a large number of studies identified a cut-off point of 8/21 for depression (Bjelland et al., 2002). For depression (HADS-D) this gave a specificity of 0.7 and a sensitivity of 0.9. In this study, the Cronbach’s alpha was 0.76.

2.2.2. The Rosenberg Self-Esteem Scale (RSE) (Rosenberg, 1965) is a self-report measure of global self-esteem. Items are rated on a 4-point rating scale ranging from 0 (‘Strongly disagree’) to 3 (‘Strongly agree’). Its total score is calculated by summing the item scores with higher scores indicating higher self-esteem. The RSE has been empirically validated and administered previously to transgender individuals (Arcelus et al., 2016; Vocks et al., 2009). In this study, the Cronbach’s alpha was 0.91.
2.2.3. The Experiences of Transgender Phobia Scale (Lombardi et al., 2001) assesses experiences of discrimination or victimization on the basis of gender identity or gender presentation. The questionnaire was based on the Transgender Violence Study and measured people’s lifetime experiences of violence and harassment and experiences of any form of economic discrimination as a result of being transgender (e.g., verbal abuse, physical abuse, fired from a job, problems getting a job, and problems getting health or medical services due to gender identity or presentation). All five items are to be rated on a four-point Likert scale ranging from 0 (‘never’) to 3 (‘several times’). This scale has been previously used with transgender individuals (Arcelus et al., 2016; Bouman et al., 2016c; Claes et al., 2015; Colizzi et al., 2014). In this study, the Cronbach’s alpha was 0.59.

2.2.4. The Multidimensional Scale of Perceived Social Support (MSPSS) (Zimet et al., 1990) is a 12-item, self-report scale designed to tap social support from family, friends, and significant others. Items are rated on a 7-point Likert scale ranging from 1 (‘very strongly agree’) to 7 (‘very strongly disagree’). The instrument includes three subscales to address these three types of support (family, friends, significant others). The mean total and subscale scores range from 1 to 7, and a higher score indicates greater perceived social support. This scale has recently been used in transgender populations (Boza & Perry, 2014; Davey et al., 2014). In this study, the Cronbach’s alpha was 0.89.

2.2.5. The Inventory of Interpersonal Problems (IIP-32) (Barkham, Hardy & Startup, 1996) measures interpersonal difficulties. It consists of 32 items to be rated on a 5-point Likert scale ranging from 0 (‘Not at all’) to 4 (‘Extremely’). There are eight
subscales of interpersonal problems: *Hard to be Assertive, Hard to be Sociable, Hard to be Supportive, Hard to be Involved, Too Dependent, Too Caring, Too Aggressive, and Too Open*. A total mean score provides a global measure of interpersonal distress. Higher subscale scores indicate greater interpersonal difficulties. The IIP-32 is a shortened version of the original IIP, yet the psychometric properties are retained; a confirmatory factor analysis demonstrated high reliability with alpha coefficients of 0.70 to 0.88 (Barkham et al., 1996). The IIP-32 has been successfully used in both non-clinical (Berry et al., 2006) and clinical samples (Bouman et al., 2016c, Davey et al., 2015]. In this study, the Cronbach’s alpha was 0.87.

2.3. Data Analysis

All quantitative data analyses were performed by means of SPSS 22 (IBM, 2013). Based on HADS-D scores, individuals were grouped into one of three categories: 1) people with no depressive disorder, 2) people with symptoms suggesting of a possible depressive disorder and, 3) people with symptoms suggesting a probable depressive disorder. For Aim 1, only transgender people not on cross-sex hormones were included in order to have a homogenous group. Both groups will be matched according to age and experienced gender. As the control group identified themselves based on the binary notion of gender (male and female), in order for the matching to be possible only transgender people who identified as male or female will be selected. Transgender non-binary people will not be included. The chi-square test statistic was used to compare the frequency with which transgender and general population adults fell into each of the three depressive symptomology categories (no, possible, or probable depressive disorder). For the remaining aims, all transgender individuals were included. For Aim 2, a binary logistic regression analysis was performed to
explore the predictive value of the other measures of psychopathology, wellbeing, and hormone use on the presence/absence of depressive symptomology. For Aim 3, frequency of inclusion in each depressive symptomology category was compared between transgender people on cross-sex hormones and those not on cross-sex hormones using the chi-square test statistic. The level of significance for all analyses was set at $p < 0.05$. See Figure 1 for an illustration of the cohorts for each aim and the exclusions.

(Insert Figure 1. about here)

3. Results
3.1. Socio-demographic characteristics of the transgender sample
The age range of the 1069 transgender individuals invited to participate was 15-79 years with a mean age of 30.4 years (SD = 13.9). Of these, 25 (2.3%) did not consent and a further 131 participants (12%) identified themselves as non-binary (i.e., not identifying with either an exclusive male or female identity) and so were excluded from the analysis. Of the remaining 913 participants, 582 (63.7%) participants identified themselves as transgender females (assigned male at birth) and 331 (36.3%) as transgender males (assigned female at birth). Of the total sample of 913 transgender people, 638 (69.9%) were not on cross-sex hormone treatment and 261 (28.9%) were on cross-sex hormone treatment. Fourteen patients had missing data, relating to either their use or not of cross-sex hormones (14; 1.5%) leaving a final sample size of (n=899).
3.2. Aim 1: Comparative analyses between transgender people not on CHT and controls.

For the first aim of the study only people not on CHT were selected (n=638). The age range of this group was 16-79 years with a mean age of 28.6 years (SD = 12.8). This group was matched by age and experienced gender with the control group. However, 46 (7.2%; 18 transgender females and 28 transgender males aged 17 and 18 with an average age of 17.3 years [SD = 0.48]) could not be matched due to insufficient numbers for that age in the control data. Therefore, this gave a final sample of 1184 participants; 592 non-CHT patients who were matched with 592 participants in the control population database. Taking these together, 436 (36.8%) were transgender and cisgender females and 748 (63.2%) were transgender and cisgender males.

In the category of ‘No Depressive Disorder’, the control group was significantly more prevalent than the transgender group. In contrast, the transgender group was significantly more prevalent in the categories ‘Possible Depressive Disorder’ and ‘Probable Depressive Disorder’ compared to the control group. This difference was statistically significant \( \chi^2(2) = 223,388, p < .001 \). Furthermore, when analysed separately by identified gender, the difference in prevalence remained statistically significant. That is, the control group was more prevalent in the ‘No Depressive Disorder’ category and the transgender group was more prevalent in the ‘Possible Depressive Disorder’ and ‘Probable Depressive Disorder’ categories in analyses that compared cisgender and transgender men \( \chi^2(2) = 149.163, p < .001 \) and cisgender and transgender women \( \chi^2(2) = 74.814, p < .001 \)).
3.3. **Aim 2: Predictors of the presence/absence of depressive disorder (probable and possible) among the whole transgender population.**

In order to explore the predictors of depression in the transgender population, the data from all of the transgender people were analyzed (n=899). Those in the category of probable and possible depressive disorder were grouped together into one category (depressive disorder). Linear regression analysis was performed with the presence or absence of depressive disorder as the dependent variable, and age, gender, self-esteem, social support, interpersonal function and victimization and presence and absence of CHT as independent variables. The results showed that four of these variables were significant predictors for a transgender person attending a health service to suffer from a depressive disorder; higher age, lower social support, lower self-esteem, and greater interpersonal problems (See Table 2).

(Insert Table 2. about here)

3.4. **Aim 3: Comparative analyses between transgender people on CHT and those not on CHT.**

Analyses comparing transgender people on CHT (n=261) with those not on CHT (n=638) found a statistically significant difference between the groups. There were more transgender people using CHT in the category of no depressive disorder
compared to those not on CHT \( \chi^2(1) = 11,556, p < .001 \). The latter group was more prevalent in the category depressive disorder (see Table 3.). A comparison of the pattern within each group found that for both transgender males and transgender females there were more transgender people in the depressive disorder category who were not on CHT compared to those who were (transgender females; \( \chi^2(1) = 6,709, p < 0.05 \)) and transgender males; \( \chi^2(1) = 4,535, p < 0.05 \)).

4. Discussion

Depression is a common mental disorder. Globally, rates of depression are high and depression is associated with great disease burden and for this reason it is one of the conditions that is targeted by the WHO’s Mental Health Gap Action Programme (WHO, 2016). While the precipitating factors are many and varied, certain groups may be at an increased risk of developing depressive symptomology. In line with this, this study found high rates of possible (13%) and probable (11%) depression in untreated treatment seeking transgender people attending a transgender health service in the UK. Overall, there was a significantly higher prevalence of transgender people reporting depressive symptomology than controls – an almost 4-fold increased risk - and this pattern was evident when comparing both males (cis and trans) and females (cis and trans). Within the full transgender group (treated and untreated), older age, less social support, lower self-esteem, and greater interpersonal problems were significant predictors of depressive symptomology, and both transgender males and
transgender females were more likely to be in the depressive disorder categories if they were not on cross-sex hormones.

While some mental health disorders, such as anxiety (McLean et al., 2011), post-traumatic stress disorder (Mendoza et al., 2016) and depression (Fellinger et al., 2018; Fisher et al., 2017) often present as more prevalent in females, with explanations linked to variations in the effects of sex hormones (e.g., estrogen and progesterone, corticotropin-releasing factor (CRF), and neurotransmitters such as serotonin) on the fight or flight response (Bangasser et al., 2016), which may vary across the menstrual cycle (Rohleder et al., 2001), here gender did not appear to differentiate between risk for depression. This suggests that the increased risk that transgender individuals appear to face may be more related to their experiences of being transgender, rather than their birth assigned physiology. Indeed, for transgender people in particular, the experience of minority stress (Meyer, 1995; 2003) is significant and likely plays a greater role (Davey et al., 2014).

Older age, less social support, lower self-esteem, and greater interpersonal problems were significant predictors of depressive symptomology in treated and untreated transgender people. These variables are often inextricably linked; those with little social support are likely to have reduced self-esteem and this may influence their interpersonal functioning. Or indeed poor interpersonal functioning may lead to difficulties in relationships which can lead to a limited social network on which one can rely on for support. Although in some circumstances individuals can develop coping mechanisms over time which can lead to reduction in depression (Nuttbrock et al., 2010), here depression was predicted by older age which may reflect the cumulative
effect over the years of the other variables (i.e., longer period of lack of social support) or greater difficulties in coming out when older and experiencing transphobia as a more recent occurrence (Singh & Bower, 2017). Identification of such predictor variables is important as it provides a richer insight into the experiences of transgender people. Rather than simply reporting that depression is higher, we seek to understand what factors might be associated with this, in order to develop ways to support transgender people. That is, to focus on the factors implicated in the development and maintenance of depression. In line with this, the finding that social support, self-esteem, and interpersonal problems are significant suggests that these could be valuable areas for clinicians to work on with their clients, in addition to addressing the presenting symptoms in the usual ways (therapy and/or pharmacological interventions) (McFarquhar et al., 2018). Interventions in other areas, with other client groups, have found effective ways to increase self-esteem (Fennell, 2006; Morton et al., 2012; Rigby & Waite, 2007) and interpersonal psychotherapy (IPT) has been shown to improve interpersonal functioning (e.g., Arcelus et al., 2011; Hara et al., 2000; Mufson et al., 2013) and these could be easily translated to the transgender population. Delivering such interventions alongside facilitating peer support, either face-to-face or online, may be one way in which clinicians can assist in developing social support for their clients. Indeed, peer support can offer avenues to greater social connectedness, increased confidence and ability to challenge stigma in a safe space, insight into health decisions from hearing shared experiences, and potentially increased awareness of mental health struggles which may lead to increases in help seeking behavior (Naslund et al., 2016).
Satisfaction with support also appears to be key (McNeil et al., 2012); i.e., quality not quantity. Indeed, being able to effectively utilize social support has been implicated in lower levels of depression in transgender women (Clements-Nolle et al., 2011) in contrast to more avoidant coping strategies (Mepham et al., 2014) and therefore working with families to ensure that the support that is being given is serving the need of the transgender person, for example in increasing self-efficacy (Bouman et al., 2016b), may be valuable. Focusing on these factors may help to reduce transgender individuals’ likelihood of experiencing depression, and/or increases in depression, when going through their transitional process.

The analysis comparing transgender individuals on cross-sex hormone treatment with those not on such treatment confirmed that there are apparent benefits to the use of hormones on depressive symptomology and reflects the benefits reported firsthand by clinicians and within the literature (Bouman et al., 2016b; Davis et al., 2014; De Vries et al., 2014; Gómez-Gil et al., 2012; Heylens et al., 2014), although these findings need to be replicated in longitudinal studies. This can be taken as further evidence to support the argument that early initiation of gender confirming treatment for transgender people is beneficial to the long term mental wellbeing of transgender individuals and that access to cross–sex hormones should be made available at the earliest possible point. Currently, many people resort to purchasing hormones via the internet which carries inherent dangers (Mepham et al., 2014). This is because the pathways to care within the UK are extremely prescriptive which serves to draw out the time taken to time to access hormones (Coleman et al., 2010; Wylie et al., 2014). This is in addition to already long waiting times to be seen by a specialist clinical service due to the limited number that exist and increasing numbers of referrals.
Changes to the infrastructure and processes available would serve to help transgender individuals access hormone treatment earlier, if desired. However, due to the cross-sectional nature of this study, the direction of effect is unknown. That is, whether the positive impact on psychological wellbeing associated with the use of CHT is a consequence of starting the process of gender role transition, or whether those who start CHT before a specialist assessment do so because they have greater self-esteem, better interpersonal relationships and more social support - possibly from other trans friends who may guide them - and are therefore in a better position to embark on CHT without the assistance of a medical professional.

The global generalizability of these findings needs to be borne in mind. Waiting times in the UK are long (currently between 12-14 months) and the UK legislation on access to free healthcare for transgender people, as well as legislation such as the Gender Recognition Act 2004 and the Sex Discrimination (Gender Reassignment) Regulations Act 1999 and 2008, mean that the experiences of transgender people in the UK may be very different from that of trans people in other countries (Davey et al., 2015). These differences are further emphasized when considering how changes to diagnosis might affect access to care differently in different countries (Beek et al., 2016). Within the UK trans population, these results may only be generalizable to transgender individuals who have chosen to access care via transgender health services, which therefore fails to capture those who have yet to seek treatment (Zucker & Lawrence, 2009). However, a major strength of this study and one which seeks to address methodological criticisms of past research (e.g., Dhejne et al., 2011) is the use of a matched control sample (transgender and controls matched on experienced gender; transgender on CHT and not on CHT); a method we have used previously (Witcomb
et al., 2015). Regarding sample size, this study is, to our knowledge, one of the largest studies in the field. It is worth noting, however, that 12% of the participants invited to participate identified themselves as being non-binary; identifying neither with their birth assigned gender, nor the opposite gender. These participants were excluded, so as to maintain homogeneity, since recent studies suggest that non-binary people may have poorer health than binary transgender people (Orre et al., 2017; Rimes et al., 2017; Warren et al., 2016; Zeluf et al., 2016). However, as the prevalence of people identifying as non-binary is increasing (Richards et al., 2016) it is possible that some of our transgender participants may ultimately endorse a non-binary gender as opposed to a binary transgender identity. Furthermore, our control population was not asked about their gender identity and so it is possible that this population may include some transgender and non-binary people. However, since the number of non-binary people seen within the service, as well as the prevalence of transgender individuals within the general population, is very low overall, this is unlikely to pose a major methodological concern. But, we do propose that in the future matching may be more accurate when done on the basis of birth assigned gender, and that binary and non-binary transgender cohorts be included within studies together. Indeed, since our control group was taken from a general population sample, it may also be useful to compare depression rates in binary and non-binary trans people with control participants from both non-clinical and clinical populations to get a better picture of the rates of depression experienced.

Overall, this study highlights the need for clinical services to properly assess depressive symptomology, and associated predictor variables, in treatment-seeking transgender individuals and to expedite the use of cross-sex hormones, where
appropriate, in order to improve mental health. Here, untreated transgender people had higher prevalence rates of possible or probable depressive disorder than controls and trans people already on cross-sex hormones. Higher age, lower self-esteem, lower social support and poorer interpersonal functioning all predicted depressive disorders. Focused interventions that primarily aim to increase self-esteem, social support and interpersonal functioning may prove to be useful in increasing the quality of life of transgender people.
References


psychological symptoms, victimization, interpersonal functioning and perceived social support. J Sex Med. 12,168-179.


Figure 1: Diagram to show the cohorts for each aim of the study and the exclusions.

**Aim 1**
- n=592
  - n=218 TF
  - n=374 TM

**Aim 2**
- n=913
  - Excluded: n=25: no consent
  - Excluded: n=131: non-binary
- N=1069
  - Excluded: n=46: no matched control available

**Aim 3**
- N=899
  - Excluded: n=14: CHT?
- CHT-
  - n=638
- CHT+
  - n=261

N=3816

Excluded:
- n=638: no matched control available
Table 1: Number of transgender (TG) people and controls with no depressive disorders, and depressive disorders (possible and probable) (n=1184)

<table>
<thead>
<tr>
<th></th>
<th>Both Genders</th>
<th>Females</th>
<th>Males</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n=1184)</td>
<td>(n=436)</td>
<td>(n=748)</td>
</tr>
<tr>
<td></td>
<td>TG (n=592)</td>
<td>Controls (n=592)</td>
<td>TG (n=218)</td>
</tr>
<tr>
<td>No depressive disorder n(%)</td>
<td>309 (26.1)*</td>
<td>539 (45.5)*</td>
<td>112 (25.7)*</td>
</tr>
<tr>
<td>Depressive disorders n(%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Possible n(%)</td>
<td>154 (13.0)</td>
<td>39 (3.3)</td>
<td>59 (13.5)</td>
</tr>
<tr>
<td>Probable n(%)</td>
<td>129 (10.9)</td>
<td>14 (1.2)</td>
<td>47 (10.8)</td>
</tr>
<tr>
<td>Total possible + probable n(%)</td>
<td>283 (23.9)*</td>
<td>53 (4.5)*</td>
<td>106 (24.3)*</td>
</tr>
</tbody>
</table>

*p<.05
Table 2. Predictive role of age, gender, self-esteem, social support, interpersonal function and victimization in transgender people with possible and probable depressive disorder (as one category) compared to transgender people with no depressive disorder.

<table>
<thead>
<tr>
<th></th>
<th>B</th>
<th>SE</th>
<th>Wald</th>
<th>Exp(B)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>.017</td>
<td>.008</td>
<td>5.028</td>
<td>1.017</td>
<td>.025</td>
</tr>
<tr>
<td>Assigned Gender</td>
<td>.230</td>
<td>.187</td>
<td>1.512</td>
<td>1.259</td>
<td>.219</td>
</tr>
<tr>
<td>CHT pre assessment</td>
<td>.009</td>
<td>.196</td>
<td>.002</td>
<td>1.009</td>
<td>.963</td>
</tr>
<tr>
<td>Global score MSPSS</td>
<td>-.015</td>
<td>.006</td>
<td>6.257</td>
<td>.985</td>
<td>.012</td>
</tr>
<tr>
<td>Total RSE</td>
<td>-.118</td>
<td>.018</td>
<td>44.706</td>
<td>.889</td>
<td>.000</td>
</tr>
<tr>
<td>Global IIP score</td>
<td>.911</td>
<td>.163</td>
<td>31.149</td>
<td>2.488</td>
<td>.000</td>
</tr>
<tr>
<td>Total Transphobia</td>
<td>.012</td>
<td>.035</td>
<td>.112</td>
<td>1.012</td>
<td>.737</td>
</tr>
<tr>
<td>Constant</td>
<td>.281</td>
<td>.622</td>
<td>.204</td>
<td>1.325</td>
<td>.651</td>
</tr>
</tbody>
</table>

a. Dependent Variable: presence/absence of depression (HADS)
Table 3. Depressive disorders based on the HADS in transgender people on cross-sex hormone treatment (CHT) and those not on cross-sex hormone treatment (n= 899)

<table>
<thead>
<tr>
<th></th>
<th>Transgender people not on CHT</th>
<th>Transgender people on CHT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N(%)</td>
<td>N(%)</td>
</tr>
<tr>
<td>All (n=638)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transgender males (n=247)</td>
<td>33 (52.4)</td>
<td>125 (50.6)</td>
</tr>
<tr>
<td>Transgender females (n=391)</td>
<td>209 (53.5)</td>
<td>169 (64.8)</td>
</tr>
<tr>
<td>All (n=261)</td>
<td>169 (64.8)</td>
<td>52 (64.2)</td>
</tr>
<tr>
<td>Transgender males (n=81)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transgender females (n=180)</td>
<td>169 (64.8)</td>
<td>117 (65.0)</td>
</tr>
<tr>
<td>No depressive disorder (Score 0-7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Possible or probable depressive disorder (Score ≥ 8)</td>
<td>304 (47.6)</td>
<td>122 (49.4)</td>
</tr>
</tbody>
</table>